Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

LONDON, December 12, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families. Following a review requested by an anonymous third party during 2010, the USPTO has concluded that the reissued claims are patentable and has issued Notices of Intent to Issue Reexamination Certificates. The prior art cited in the reexaminations was unsuccessful in invalidating the patents.

The four patents (US 7,459,547, US 7,732,593, US 7,772,203 and US 7,750,144) form part of the foundational "Zamore Design Rule" patent families that disclose various efficacy-enhancing methods and structural elements for RNAi therapeutics. Silence has exclusively licensed three "Zamore Design Rule" patent families in their entirety for applications in the human healthcare field from the University of Massachusetts Medical School. The three patent families generally disclose methods of enhancing the silencing activity of RNAi agents through certain structural modifications. The claims associated with the reexaminations include coverage for methods of enhancing silencing of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin RNA (shRNA) molecules.

Thomas Christély, Chief Executive Officer of Silence Therapeutics, said: "We are very pleased that the USPTO has reissued these four patents. This outcome sends a clear message regarding the strength of Silence's intellectual property. We believe that there is significant value in the Zamore technology as a fundament
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... 2013  Dr. Gerald Zon , ... recently launched a new blog in conjunction with TriLink ... ), focuses on what,s trending in the field of ... leaders, discussions of research presented at conferences and meetings, ... Dr. Zon (PhD Princeton University 1971) developed automated synthesis ...
(Date:5/20/2013)... , May 20, 2013 Cempra, Inc. ... developing differentiated antibiotics to meet critical medical needs ... that it presented data at the American Thoracic ... Philadelphia demonstrating the antibacterial and enhanced ... prior Phase 2 clinical trial in outpatients with ...
(Date:5/20/2013)... May 20, 2013 Researchers from the ... connection between lower back pain, and the acne causing P.acnes ... the system the bacteria seek out oxygen deprived location to ... the spinal column, P.acnes has the ability to live in ... Fernando Perez, a spokesman for “ The best acne treatment ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Executive Officer of BioMarin, will host a ... 28, at 5:00 p.m. ET to discuss ... Dial-in Number:  888.396.2386International Dial-in Number:  617.847.8712Participant Code: ...
... 28, 2011 The Japanese nuclear crisis has caused ... shortages not only in Japan, but as far away ... potassium iodide does not provide generalized radiation protection because ... being bombarded with orders as the radiation hysteria mounts. ...
... CAMBRIDGE, Mass. -- In recent years, many airplane manufacturers ... which consist of high-strength fibers, such as carbon or ... materials are stronger and more lightweight than aluminum, but ... because their surfaces usually don,t reveal underlying problems. ...
Cached Biology Technology:BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET 2Shortages of Potassium Iodide as Radiation Panic Drives Demand 2MIT engineers devise new way to inspect materials used in airplanes 2
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
(Date:5/18/2013)... 2013) Research presented at Digestive Disease Week ... through diet and lifestyle. , Individuals suffering ... muscle strength, fatigue and poor quality of life. ... in remission. A randomized, double blind, placebo-controlled study ... supplementation corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... By day, insects provide the white noise of the South, ... typical year, the Southern air hangs heavy from the humidity ... to more than 140 species of frogs, toads and salamanders, ... If the ponds and swamps are the auditorium for their ... Research and Monitoring Initiative, or ARMI, have front-row seats. ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... July 28, 2011 A paper published today in ... novel, proprietary monoclonal antibody (FI6) discovered in a collaboration ... Biomedicine ("IRB") and the UK Medical Research Council (MRC). ... 16 hemagglutinin subtypes of influenza A and represents an ...
... Escape responses are some of the most studied ... brain processes sensory information. The ability to evade predators ... selection. Animals explore their environment to find food, find ... escape responses to avoid predators, thereby increasing their chances ...
... approach which focuses on understanding the complex relationships ... of an aggressive form of breast cancer, researchers for ... in the blood that change in abundance long before ... Christopher Kemp, Ph.D., and Samir Hanash, M.D., Ph.D., members ...
Cached Biology News:Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A viruses 2Elusive prey 2Using a 'systems biology' approach to look under the hood of an aggressive form of breast cancer 2
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Cryo/CryoPlus Inventory Racks for cryogenic ... with cardboard or stainless steel ... 5ml cryo vials. Vapor ... available. Platform risers to ...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: